| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTK2B |
| Uniprot No | Q14289 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1009 aa |
| 活性数据 | MSGVSEPLSRVKLGTLRRPEGPAEPMVVVPVDVEKEDVRILKVCFYSNSFNPGKNFKLVKCTVQTEIREIITSILLSGRIGPNIRLAECYGLRLKHMKSDEIHWLHPQMTVGEVQDKYECLHVEAEWRYDLQIRYLPEDFMESLKEDRTTLLYFYQQLRNDYMQRYASKVSEGMALQLGCLELRRFFKDMPHNALDKKSNFELLEKEVGLDLFFPKQMQENLKPKQFRKMIQQTFQQYASLREEECVMKFFNTLAGFANIDQETYRCELIQGWNITVDLVIGPKGIRQLTSQDAKPTCLAEFKQIRSIRCLPLEEGQAVLQLGIEGAPQALSIKTSSLAEAENMADLIDGYCRLQGEHQGSLIIHPRKDGEKRNSLPQIPMLNLEARRSHLSESCSIESDIYAEIPDETLRRPGGPQYGIAREDVVLNRILGEGFFGEVYEGVYTNHKGEKINVAVKTCKKDCTLDNKEKFMSEAVIMKNLDHPHIVKLIGIIEEEPTWIIMELYPYGELGHYLERNKNSLKVLTLVLYSLQICKAMAYLESINCVHRDIAVRNILVASPECVKLGDFGLSRYIEDEDYYKASVTRLPIKWMSPESINFRRFTTASDVWMFAVCMWEILSFGKQPFFWLENKDVIGVLEKGDRLPKPDLCPPVLYTLMTRCWDYDPSDRPRFTELVCSLSDVYQMEKDIAMEQERNARYRTPKILEPTAFQEPPPKPSRPKYRPPPQTNLLAPKLQFQVPEGLCASSPTLTSPMEYPSPVNSLHTPPLHRHNVFKRHSMREEDFIQPSSREEAQQLWEAEKVKMRQILDKQQKQMVEDYQWLRQEEKSLDPMVYMNDKSPLTPEKEVGYLEFTGPPQKPPRLGAQSIQPTANLDRTDDLVYLNVMELVRAVLELKNELCQLPPEGYVVVVKNVGLTLRKLIGSVDDLLPSLPSSSRTEIEGTQKLLNKDLAELINKMRLAQQNAVTSLSEECKRQMLTASHTLAMDAKNLLDAVDQAKVLANLAHPPAE |
| 分子量 | 142.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于重组人PTK2B(蛋白酪氨酸激酶2β)蛋白的参考文献及摘要概括：
1. **文献名称**：*Structural and functional characterization of PTK2B/Pyk2 kinase*
**作者**：Chen, S. et al.
**摘要**：研究解析了PTK2B激酶结构域的晶体结构，揭示了其自抑制机制，并通过重组表达验证了其在神经元突触可塑性中的调控作用，为神经退行性疾病药物开发提供依据。
2. **文献名称**：*Recombinant human PTK2B expression in HEK293 cells and its role in calcium signaling*
**作者**：Liu, Y. et al.
**摘要**：报道了通过HEK293细胞高效表达重组人PTK2B蛋白的方法，并证明其在钙离子依赖性信号通路中激活MAPK/ERK途径的关键作用。
3. **文献名称**：*PTK2B promotes cancer invasion by regulating integrin signaling*
**作者**：Park, J.H. et al.
**摘要**：利用重组PTK2B蛋白进行体外实验，发现其通过整合素-粘着斑复合物促进肿瘤细胞迁移和侵袭，提示其作为癌症治疗靶点的潜力。
4. **文献名称**：*Association of PTK2B with Alzheimer’s disease risk and amyloid-beta pathology*
**作者**：Hernández, F. et al.
**摘要**：通过基因和蛋白功能分析，发现PTK2B表达异常与阿尔茨海默病风险相关，重组蛋白实验表明其参与β-淀粉样蛋白毒性信号的传导调控。
(注：以上文献为示例性内容，实际文献需通过PubMed或Web of Science等数据库查询近期研究。)
**Background of Recombinant Human Protein Tyrosine Kinase 2 Beta (PTK2B):**
Protein Tyrosine Kinase 2 Beta (PTK2B), also known as Focal Adhesion Kinase 2 (FAK2) or Proline-Rich Tyrosine Kinase 2 (PYK2), is a non-receptor cytoplasmic tyrosine kinase encoded by the *PTK2B* gene. It belongs to the FAK family of kinases and shares structural similarities with Focal Adhesion Kinase (FAK/PTK2), including an N-terminal FERM domain, a central kinase domain, and a C-terminal focal adhesion-targeting (FAT) domain. Unlike FAK, PTK2B lacks intrinsic kinase activity and is primarily activated by calcium signaling, G-protein-coupled receptors (GPCRs), or growth factor stimuli.
PTK2B regulates diverse cellular processes, including cell migration, proliferation, survival, and cytoskeletal reorganization, by integrating extracellular signals with intracellular pathways. It interacts with key signaling molecules like Src-family kinases, Grb2. and PI3K, modulating downstream effectors such as MAPK, JNK, and PI3K-AKT pathways. Its expression is prominent in neuronal tissues, osteoclasts, and immune cells.
Dysregulation of PTK2B is implicated in neurodegenerative diseases (e.g., Alzheimer’s disease), cancer metastasis, and inflammatory disorders. In Alzheimer’s, PTK2B polymorphisms are linked to amyloid-beta toxicity and synaptic dysfunction. Recombinant human PTK2B is widely used in biochemical studies to dissect its role in signaling networks and to screen therapeutic inhibitors targeting its kinase activity or protein interactions, offering potential for treating PTK2B-associated pathologies.
×
